Parotid Gland Metastasis of Breast Cancer: Case Report and Review of the Literature

Katsutoshi Ando, Norio Masumoto, Masaaki Sakamoto, Kou Teraoka, Takako Suzuki, Terumasa Kurihara, Satoko Abe, Mitsuhiro Tozaki, Eisuke Fukuma, Kazuei Hoshiba

© 2011 S. Karger GmbH, Freiburg
1661-3791/11/0066-0471 $38.00/0
Accessible online at: www.karger.com/brc

Introduction

In the head and neck tumors, salivary gland tumors, especially metastatic, are rare clinical events. Metastatic parotid gland involvement accounts for approximately 9–14% of all parotid tumors [1]. Metastasis to the parotid gland from breast cancer is extremely rare, and to our knowledge only 14 cases have been reported between 1982 and 2010 [2–10]. We report a case of invasive lobular carcinoma of the breast which spread to the parotid gland, and we summarize the 14 cases that have been reported.
Case Report

A 67-year-old female patient presented to our institution with a left-sided breast lump and swelling in the left axillary lymph nodes in September 2007. We performed a biopsy, and histology showed a Bloom and Richardson grade 3 invasive lobular carcinoma. Immunohistological study was negative for estrogen and progesterone receptors, and positive (score 3) for human epidermal growth factor receptor 2 (HER2). A routine metastatic workup revealed metastasis to the bilateral cervical and supravacular lymph nodes, and the clinical stage was diagnosed as cT1N3M1(stage IV). The patient received 6 cycles of FEC-60 (fluorouracil 500 mg/m², epirubicin 60 mg/m², cyclophosphamide 500 mg/m²) followed by weekly paclitaxel 80 mg/m² and trastuzumab. Chemotherapy resulted in a clinical complete response (revealed by positron emission tomography (PET)-computed tomography (CT) scan), and a left mastectomy with axillary clearance surgery was performed, followed by radiotherapy (45 Gy) to the bilateral neck, supravacular space, left axilla, and precordium. Moreover, we continued the administration of weekly trastuzumab because the tumor in the breast responded favorably to this drug resulting in a histological grade 2b.

In May 2009 (11 months after the operation), the patient presented to the Otolaryngology Department with a swelling in her left parotid gland, and a PET-CT scan revealed accumulation of standardized uptake value (SUV) 9.8 in that region (fig. 1). A primary parotid tumor was suspected, and a partial parotidectomy performed. Histology showed a poorly differentiated HER2-positive adenocarcinoma (fig. 2), resulting in the diagnosis of parotid gland metastasis from the breast. Capecitabine 1,650 mg/m²/day was started in addition to trastuzumab. Although a dose reduction of capecitabine was needed due to a grade 2 hand-foot syndrome, the size of the tumor in the parotid gland was reduced and the abnormal accumulation had improved on PET-CT in November 2009 (4 months after addition of capecitabine).

Discussion

Invasive ductal carcinoma is the most invasive histological pattern of breast cancer. Distant spread through the lymphatic route occurs to the mediastinal and supravacular lymph nodes. Also hematogenous spread occurs and leads to metastasis to lung, liver, bone, adrenals, and brain [10]. However, metastasis to the parotid gland is a very rare clinical event for breast cancer. In a review of autopsy studies which included 167 cases of breast cancer, only 1 case of metastasis to the parotid gland was detected [11]. Also, a search of the MEDLINE database (1982–2010) revealed merely 14 cases (table 1) [2–10]. One reason for the rarity of this event is the anatomical location. Metastasis to the parotid gland usually arises from primaries in the head and neck. The parotid gland is divided into paraglandular lymph nodes, intraglandular lymphatics, and parenchyma. The paraglandular and intraglandular lymphatics are common sites for metastasis from squamous cell carcinoma and melanoma of the scalp, ear, and the forehead by direct lymphatic drainage. On the other hand, parenchymal metastasis is considered to occur via hematogenous rather than lymphatic spread [12, 13]. However, few reports document which area in the parotid gland is affected by metastasis, and the metastatic process remains to be elucidated. To our knowledge, 11 of the 14 patients had left parotid gland metastasis (5 primary breast carcinomas in the left and 5 in the right breast; 1 case unknown), and 3 patients had metastasis to the right parotid gland (1 primary in the left and 2 in the right breast). Since 5 (45.5%) of the 11 patients with left parotid involvement had a primary carcinoma in the right breast, it is possible that the spread occurred via hematogenous as opposed to direct lymphatic metastasis.

For the treatment of this metastasis, parotidectomy, radiation, chemotherapy, and hormone therapy were performed. Regardless of the metastatic pathway, generalized treatment such as chemo- and hormone therapy is needed. Because immunohistochemical analysis in our case had revealed the tumor to be negative for estrogen and progesterone receptors and positive for HER2, we continued to administer trastuzumab postoperatively. Trastuzumab combined with chemotherapy drugs such as paclitaxel improves outcomes among women with surgically removed HER2-positive breast cancer [14]. It also improves disease-free survival if continued after

![Fig. 1. PET-CT scan revealed accumulation of SUV 9.8 in the left parotid gland.](image1)

![Fig. 2. Photomicrograph of a section through the parotid tumor revealing a metastatic invasive lobular carcinoma of the breast (H&E ×400).](image2)
adjuvant chemotherapy [15]. However, the effect of post-operative adjuvant chemotherapy in stage IV breast cancer patients is controversial.

In spite of various treatments, in this case, the patient experienced a relapse 11 months after operation. At that time, there were some treatment options such as to continue or discontinue trastuzumab (change to lapatinib) and start or not continue trastuzumab (change to lapatinib) and start or not start chemotherapies. Lapatinib, a tyrosine kinase inhibitor of HER2 and epidermal growth factor receptor, is an active combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy [16]. We started capecitabine in addition to trastuzumab, which is one of the strategies applied in HER2-positive breast cancer, and this approach proved effective.

The case presented here had an unusual clinical course. Oncologists should keep in mind that the clinical course or imaging findings are not always in line with common patterns. Rare presentations such as in our case are possible, and we should always strive for a histopathologic diagnosis.

Disclosure Statement
K.A. desclaims that he has no financial or personal relationships with other people or organizations that could inappropriately influence his actions. The other authors did not provide a conflict of interest statement.

References